StockLearn from Clustermicro · Stock Breakout ScannerStockLearn

Sudeep Pharma Limited (SUDEEPPHRM)

Pharma · NSE · end-of-day 2026-10-19

₹1,003.30

Day change

+0.26%

1-year

+29.6%

From 52-week high

-25.4%

Weinstein stage

Stage 2

Minervini template

—

Sudeep Pharma Limited closed at ₹1,003.30 on 2026-10-19, up 30% over the past year, 25% below its 52-week high. Weinstein's stage analysis reads stage 2 - advancing. Over the year its annualised volatility was about 48%, with a largest fall of 32% from a peak.

About Sudeep Pharma Limited

Sudeep Pharma Limited manufactures pharmaceutical ingredients and specialty products used in healthcare and pharmaceutical applications. Increasing pharmaceutical production, healthcare demand, and opportunities in specialized ingredients provide long-term growth potential. Product development, capacity expansion, and international markets can support growth. Regulatory requirements, raw-material costs, customer concentration, competition, and export demand remain important factors.

Price, RSI and MACD

6M1Y

Price · +51.0% over the period

RSI (14) · 36.0

MACD (12, 26, 9) · histogram -18.68

Price · +29.6% over the period

RSI (14) · 36.0

MACD (12, 26, 9) · histogram -18.68

Price: daily close adjusted for splits and bonuses, dashed line the 150-day moving average. MACD: green line, orange dashed signal, bars the histogram. Longer periods are drawn from every second or third session.

Fundamentals

Market cap	Sales (TTM)	Net profit (TTM)	P/E	EPS (TTM)	P/B	ROE	Debt / equity	Free cash flow	EV / EBITDA	Beta
₹11,332 cr	—	—	61.1	16.24	12.83	20.8%	0.17	₹-49 cr	45.6	0.78

Quarterly results

Quarter	Sales ₹ cr	Net profit ₹ cr	EPS	EPS YoY	Sales YoY	Net margin
Jun 2026	158	41	3.59	—	—	25.6%
Mar 2026	182	48	4.38	—	—	26.6%
Dec 2025	172	—	—	—	—	—
Sep 2025	163	47	4.20	—	—	28.8%

Consolidated · EPS restated onto today's share count after splits and bonuses · net profit as filed.

Minervini SEPA — earnings checks 0 of 0 pass

Check	Result
Latest quarter EPS up 25%+ on a year ago	— Not assessable
EPS growth accelerating over 3 quarters	— Not assessable
Sales up 25%+, or sales growth accelerating	— Not assessable
Annual EPS up 25%+ in each of the last 2 years	— Not assessable
Net margin above the same quarter last year	— Not assessable

Investor methods

Method	Checks	Score	Verdict
Turtle	✗ Close above the prior 55-session high · 1,378.00 ✗ Close above the prior 20-session high · 1,249.80 ✗ Close below the prior 20-session low · 981.60 Donchian channel breakout - the Turtle traders' entry.		No signal
Weinstein	Stan Weinstein's stage analysis on the 30-week moving average.		Stage 2 - advancing
Graham	✗ Price at or below the Graham number · Graham number 169.04 ✗ P/E 15 or less · P/E 61.8 ✗ P/B 1.5 or less (or P/E x P/B 22.5 or less) · P/B 12.83 ✓ Current ratio 2 or more · 3.09 — 10 years of positive earnings, 20 of dividends · history not held Benjamin Graham's defensive-investor tests.	17/100	Expensive

Each method's own rules applied to this stock - information, not a buy or sell signal. All were tested on 2024-26 data; only the Minervini trend template showed a consistent edge.

Pharma sector — top 10 by 1-year return

Stock	1M %	3M %	6M %	1Y %	3Y %	5Y %	P/E	P/B	ROE %	ROCE %	ROA %	D/E	EV/EBITDA	₹ Cr	Sales TTM ₹ Cr	Profit TTM ₹ Cr	EPS	Beta
SUDEEPPHRM this stock	-13.1	+15.8	+51.0	—	—	—	61.1	12.83	20.8	—	—	0.17	45.6	11,332	—	—	16.2	0.78
BLISSGVS	-8.0	+29.9	+147.2	+312.3	+606.5	+476.9	48.7	5.57	11.5	16.8	—	0.00	29.3	6,650	1,005	142	12.9	1.10
VENUSREM	+0.7	-5.9	+55.8	+252.6	+518.8	+242.4	18.3	3.21	16.8	21.9	—	0.00	13.7	2,130	811	116	86.9	0.88
INDSWFTLAB	-5.7	+50.4	+153.3	+247.2	+287.1	+472.2	51.6	2.21	3.2	3.9	—	0.01	33.4	3,056	665	57	6.8	0.78
MOREPENLAB	+0.5	+108.6	+194.2	+152.6	+242.7	+132.7	47.5	5.34	7.9	10.1	—	0.16	40.2	6,657	1,951	140	2.6	1.46
SHILPAMED	-14.2	+40.1	+113.1	+146.1	+421.3	+189.7	57.3	6.61	9.8	11.4	—	0.25	—	17,130	1,682	297	15.3	0.87
RUBICON	-15.1	-1.7	+60.3	+140.3	—	—	83.8	19.08	22.4	—	—	0.20	61.3	24,587	1,936	288	17.7	0.34
LAURUSLABS	+5.9	+32.7	+83.2	+129.9	+421.9	+235.3	88.9	21.09	18.2	17.9	—	0.45	62.0	1.12L	8,839	1,252	23.3	0.74
ZIMLAB	+2.0	+14.2	+73.3	+101.9	+17.5	—	168.5	2.50	2.1	5.5	—	0.42	21.1	740	397	4	0.8	0.75
ACUTAAS	-5.4	-11.0	+35.0	+97.5	—	—	69.0	16.11	24.0	31.7	—	0.02	49.9	26,636	1,462	387	47.2	0.77
IOLCP	-9.8	+17.8	+108.9	+87.8	+99.0	+56.2	32.0	2.99	7.9	10.7	—	0.07	20.7	5,376	2,524	168	5.7	1.13

A blank in a return column means the stock is younger than that window. P/B and ROE come from each company's own filings where held.

Pharma stocks of a similar size

Akums Amagi Media Labs Limited Corona Remedies Limited Park Medi World Limited Viyash Scientific Limited Concord Biotech Limited Strides Pharma Science Limited Marksans Pharma Limited

The live scanner - every stock ranked, filtered by method, stage and sector, with interactive charts - is in the StockLearn app. Open the StockLearn scanner →

Prices as of 2026-10-19, end of day, from NSE. Fundamentals from each company's own exchange filings (XBRL), EPS restated for splits and bonuses. Figures may be delayed and are for information only.

For research & education only — not investment advice. The methods, checks and verdicts are automated rules applied to public data, not buy/sell recommendations. StockLearn is an independent product of ClusterMicro Technologies, not affiliated with or endorsed by the NSE or any exchange. ClusterMicro Technologies is not a SEBI-registered investment adviser. Consult a SEBI-registered adviser before investing.

Terms · Privacy · Disclaimer · Refund · Contact